BioSpace News Archive

Fact.MR, Dubai: The global blood collection tubes for liquid biopsy market is exhibiting a steady growth owing to advanced healthcare facilities and favorable medical reimbursement policies.

The report highlights trends prevailing in the global radiology information systems (RIS) market along with the driver and restraints pertaining to the market growth.

The event represents the ongoing accomplishments of Humanigen during a transformational year in developing lenzilumab for the treatment of newly hospitalized patients with COVID-19, and its intentions to continue to develop lenzilumab for the treatment of CAR-T, GvHD, and CMML.

The American Diabetes Association®, along with the nation’s leading diabetes organizations, unveiled Let’s Talk Insulin , a campaign commemorating the 100th anniversary of the discovery of insulin.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis

A connective tissue protein known to support the framework of organs also encourages immune responses that fight bacterial infections, while restraining responses that can be deadly in the condition called sepsis, a new study finds.

Sensei Biotherapeutics, today announced that it is reprioritizing its pipeline programs to focus on its product candidates, including its multi-antigenic next generation ImmunoPhage candidate, now referred to as SNS-401-NG, and its monoclonal antibody SNS-VISTA (V-set Immunoglobulin Domain Suppressor of T cell Activation) candidate.

Zealand has entered an arrangement with Danske Bank A/S to act as exclusive manager under the program.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that it has commenced an underwritten public offering of $400 million of shares of its common stock.

Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced that it has commenced an underwritten public offering of shares of its common stock.